Retinal Vein Occlusion
📧 Sign up to get email alerts when something new happens for Retinal Vein Occlusion.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-19EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
EMA authorised Opuviz (aflibercept) by Samsung Bioepis NL B.V. for treating several retinal conditions including wet age-related macular deg…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: An Assistant Model for Anti-VEGF Therapy Decision [NA]
This document reports a clinical trial update about an assistant model designed to aid decision-making for anti-VEGF therapy in retinal dise…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Retinal Clinical Assessment With AI-derived Quantitative Information
This clinical trial update describes an AI-derived retinal imaging assessment intended to provide quantitative information across several re…
-
EMA approval · 2025-12-10EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) from Celltrion Healthcare Hungary Kft. for multiple ocular conditions including wet age-related macul…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion [Phase 2]
Clinical trial update for a Phase 2 safety and proof-of-concept study of ANXV (Annexin A5) in patients with non-proliferative diabetic retin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: High-throughput Large-model-based AI-assisted Diagnosis Using OCT
A clinical trial update for a high-throughput AI system using OCT for retinal disease diagnosis; the study is not yet recruiting.
-
EMA approval · 2025-11-21EMA Authorised: Eiyzey (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorised Eiyzey (aflibercept) from Zaklady Farmaceutyczne Polpharma S.A. for multiple retinal diseases, including wet age-related …
-
FDA approval · 2025-11-19FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)
The FDA approved a supplemental application for EYLEA HD (aflibercept) by Regeneron, introducing a high-dose formulation.
-
EMA approval · 2025-11-13EMA Authorised: Afiveg (aflibercept) — STADA Arzneimittel AG
The EMA has authorised Afiveg, an aflibercept product by STADA, for multiple retinal conditions including wet age-related macular degenerati…
-
FDA approval · 2025-11-12FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
The FDA approved a supplemental Biologics License Application for BYOOVIZ (ranibizumab-nuna) from Biogen, expanding regulatory clearance for…
-
EMA approval · 2025-11-12EMA Authorised: Eyluxvi (aflibercept) — Biolitec pharma Limited Zweigniederlassung Jena
EMA authorised Eyluxvi (aflibercept) from Biolitec pharma Limited Zweigniederlassung Jena for treatment of wet age-related macular degenerat…
-
EMA approval · 2025-11-07EMA Authorised: Baiama (aflibercept) — Formycon AG
EMA authorised Baiama, a biosimilar aflibercept from Formycon AG, for multiple retinal diseases including wet age-related macular degenerati…
-
EMA approval · 2025-11-07EMA Authorised: Ahzantive (aflibercept) — Formycon AG
EMA authorised Ahzantive (aflibercept) from Formycon AG for several retinal diseases including wet age-related macular degeneration and diab…
-
EMA approval · 2025-11-04EMA Authorised: Vgenfli (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorized Vgenfli (aflibercept) from Polpharma for multiple retinal diseases, including wet age-related macular degeneration, macul…
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab [Phase 4]
Phase 4 trial evaluating traditional Chinese medicine plus ranibizumab for cystoid macular edema due to retinal vein occlusion has completed…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema
Clinical trial update examining the aqueous humor proteome in retinal vein occlusion with macular edema.
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period [Phase 4]
Phase 4 trial comparing post-intravitreal injection pain scores when using loteprednol etabonate, bromfenac sodium, or artificial tears in p…
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: Effect of Video Viewing on Intravitreal Injection Experience [NA]
A recruiting clinical trial studying whether video viewing during intravitreal injections improves patient experience in age-related macular…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients [Phase 1]
A completed Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of IVT MHU650 in macular edema patients. The trial also …
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases [EARLY_Phase 1]
An early-phase clinical trial from Shanghai BDgene is evaluating a VEGFA-targeting gene therapy for neovascular age-related macular degenera…
-
EMA withdrawal · 2025-04-14EMA Application withdrawn: Skojoy (aflibercept) — Amgen Technology (Ireland) UC
EMA has withdrawn the marketing authorization application for Skojoy (aflibercept) submitted by Amgen Technology (Ireland) UC. The applicati…
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Optical Coherence Tomography in Retinal Vein Occlusion
Assiut University is conducting a clinical trial to evaluate Optical Coherence Tomography in retinal vein occlusion. The study status is not…
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients [EARLY_Phase 1]
Phase 1 trial evaluating intravitreal aflibercept 8 mg for resistant diabetic macular edema, retinal vein occlusion, and myopic choroidal ne…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment [Phase 4]
Phase 4 trial evaluating VEGF level changes in retinal vein occlusion patients during anti-VEGF therapy has been terminated with results pos…
-
CLINICAL_TRIALS trial_result · 2025-01-22Clinical Trial Update: Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients with Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection [NA]
Clinical trial update reporting functional and anatomical outcomes of the dexamethasone intravitreal implant for resistant macular edema due…